<DOC>
	<DOC>NCT01716104</DOC>
	<brief_summary>The purpose of this study is: - To assess safety of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia and risk of progression. - To assess efficiency of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia and risk of progression.</brief_summary>
	<brief_title>Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1. Male patients 45 to 60 y.o. inclusive with a documented diagnosis of Benign prostatic hyperplasia. 2. Lower urinary tract symptoms having been experienced for 3 months and longer. 3. Total IPSS score (International Prostate Symptome Score) of 8 to 15. 4. Prostate volume of more than 30 cm3. 5. Maximal urinary flow rate of 1015 mL/sec. 6. Micturition volume of 125350 mL. 7. Residual volume of less than 100 mL. 8. Serum PSA level of less than 4 ng/mL. 9. Use of and compliance with contraceptive methods during the trial and for 30 days upon completion of participation in the trial. 10. Presence of the patient's information sheet (informed consent form) for participation in the clinical trial. 1. Invasive therapies for BPH including a transurethral prostatic resection, thermotherapy, microwave therapy, transurethral needle ablation, stenting , etc. 2. Malignant oncological disease of the urogenital system as well as malignancies of any other localization during last 5 years. 3. Acute urinary retention within 3 months before inclusion in the trial. 4. Neurogenic dysfunctions and bladder ears. 5. Urinary stone disease. 6. Urethral stricture, bladder neck sclerosis. 7. History of operative aids for pelvic organs. 8. Urogenital infections in the phase of active inflammation. 9. Systematic administration of agents exhibiting effects on bladder function and urine production. 10. Exacerbation or decompensation of chronic diseases affecting the possibility of patients to participate in the clinical trial, including severe concurrent cardiovascular conditions and disorders of the nervous system, renal and hepatic insufficiency. 11. History of administration of testosterone 5alphareductase inhibitors (finasteride, dutasteride). 12. History of polyvalent allergy. 13. Allergy/intolerance to any component of drug agents used in the therapy. 14. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency. 15. Administration of drugs specified as "Prohibited concomitant therapy", within 3 months before enrollment. 16. Exacerbation or decompensation of chronic diseases affecting the possibility of patients to participate in the clinical trial. 17. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal incapacity or limited legal capacity. 18. Legal incapacitation or limited legal capacity. 19. Patients, who, in the investigator's opinion, will fail to observe the requirements during the trial or adhere to the studied drug administration procedure. 20. Participation in other clinical trials within 3 months before enrolment in this trial. 21. Presence of other factors, complicating the patient's participation in the trial (e.g., planned lengthy business and other trips). 22. A patient is a part of the center's research staff, taking a direct part in the trial, or an immediate family member of the investigator. Immediate family members are defined as spouses, parents, children or siblings, regardless of whether full blood or adopted. 23. The patient is employed with Scientific Production Firm Materia Medica Holding LLC, i.e. is the company's employee, parttime employee under contract, or appointed official in charge of the trial, or their immediate family.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>